GlassScriptPhysician profile
Lawrence M Lewandowski
NPI 1134191422
$6,738.01
in general payments reported to CMS, 2019-2025
34 companies · $691 in 2025
The $691 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $997 · 2020: $494 · 2021: $1,268 · 2022: $903 · 2023: $1,125 · 2024: $1,260 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,075.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,566.85 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,070.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $521.84 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $479.65 | 2021-2025 | |
| Lilly USA, LLC | $423.85 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $356.13 | 2019 | |
| Dexcom, INC. | $313.48 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Genentech USA, INC. | $263.89 | 2019-2022 | |
| Abbott Laboratories | $258.03 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.18 | 2019-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $190.32 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $127.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $115.03 | 2019-2024 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $78.72 | 2021 | |
| Pfizer INC. | $76.03 | 2019-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $73.56 | 2023-2024 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $60.14 | 2022 | |
| Astellas Pharma US INC | $59.69 | 2024-2025 | Veozah |
| Shield Therapeutics INC | $55.32 | 2024 | |
| Alkermes, INC. | $51.36 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $48.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.86 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.63 | 2019-2020 | |
| Optinose US, INC. | $33.11 | 2021 | |
| Esperion Therapeutics, INC. | $30.70 | 2022-2024 | Nexletol |
| Amarin Pharma, INC. | $29.24 | 2020-2022 | |
| Allergan, INC. | $28.95 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $26.67 | 2021 | |
| Hologic Sales and Service, LLC | $21.15 | 2024 | Aptima |
| Otsuka America Pharmaceutical, INC. | $20.82 | 2024 | Rexulti |
| Tactile Systems Technology INC | $19.10 | 2024 | Flexitouch Plus, Entre Plus |
| Sanofi-Aventis U.S. LLC | $18.01 | 2021 | |
| Philips North America LLC | $12.24 | 2022 | |
| Eisai INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Lewandowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.